Merck & Co Inc【0QAH】株式ニュース

	リアルタイム株価	レベル2
Forex

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

IN BRIEF: Merck trial shows Koselugo effective in treating adults

d AstraZeneca PLC - Pharmaceutical companies based in Rahway, New Jersey and Cambridge, England, respectively - Phase ...

Merck cuts earnings guidance as acquisitions weigh on bottom line

Merck & Co Inc on Thursday reported steady top-line growth, though profit took a hit due to the cost of recent acquis ...

IN BRIEF: Merck and Daiichi Sankyo's patritumab effective in phase 3

d Daiichi Sankyo Co Ltd - Rahway, New Jersey-based and Tokyo-based pharmaceutical companies - Joint-developed monoclon ...

TOP NEWS: Merck swings to second-quarter profit; trims profit guidance

Merck & Co Inc on Tuesday reported a swing to profit in the second quarter, but lowered its guidance for annual earni ...

Merck & Co enhances ophthalmology portfolio with EyeBio acquisition

Merck & Co Inc on Wednesday said it has agreed to acquire Eyebiotech Ltd for up to USD3 billion, as the company also ...

Merck & Co raises annual outlook thanks to first quarter boost

Merck & Co Inc on Thursday raised its outlook, after posting a strong first quarter. The Rahway, New Jersey-based ph ...

IN BRIEF: Merck hails positive data on cervical cancer drug, Keytruda

Rahway, New Jersey-based pharmaceutical maker - Announces that the Phase 3 KEYNOTE-A18 trial, showed KEYTRUDA, in comb ...

Merck and Astellas drugs get priority review in US and Japan

Merck & Co Inc announced on Tuesday that its cancer treatment Keytruda with chemotherapy has been granted priority re ...

TOP NEWS: Merck books 2023 growth despite gefapixant rejection hit

Merck & Co Inc on Thursday said sales jumped in the fourth quarter and in all of 2023 as it eyes future growth Sales ...

IN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon sale

LC - London-based venture capital firm investing in "breakthrough" biotechnology companies - Expects USD18.6 million n ...

Merck to buy Harpoon Therapeutics for about USD680 million

Merck & Co Inc on Monday said it is diversifying its oncology pipeline as it has entered an agreement to buy Harpoon ...

Astellas, Merck, Pfizer celebrate US approval for Keytruda plus Padcev

Astellas Pharma Inc, Merck & Co Inc and Pfizer Inc on Friday announced expanded approval in the US for Keytruda combi ...

Merck gets US FDA nod for Welireg, as trial with Moderna bears fruit

Merck & Co Inc on Friday said its drug belzutifan was approved by the US Food & Drug Administration. The news follow ...

Merck reports mixed updates for cancer treatment, Keytruda

Merck & Co Inc on Friday and Monday updated investors on two developments regarding its cancer treatment, Keytruda. ...

TOP NEWS: Merck hails Daiichi Sankyo partnership but will take charge

Merck & Co on Thursday reported a strong rise in third-quarter revenue and a jump in profit, as it raised its full-ye ...

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Merck & Co Inc (0QAH)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

0QAH ニュース

IN BRIEF: Merck trial shows Koselugo effective in treating adults

Merck cuts earnings guidance as acquisitions weigh on bottom line

IN BRIEF: Merck and Daiichi Sankyo's patritumab effective in phase 3

TOP NEWS: Merck swings to second-quarter profit; trims profit guidance

Merck & Co enhances ophthalmology portfolio with EyeBio acquisition

Merck & Co raises annual outlook thanks to first quarter boost

IN BRIEF: Merck hails positive data on cervical cancer drug, Keytruda

Merck and Astellas drugs get priority review in US and Japan

TOP NEWS: Merck books 2023 growth despite gefapixant rejection hit

IN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon sale

Merck to buy Harpoon Therapeutics for about USD680 million

Astellas, Merck, Pfizer celebrate US approval for Keytruda plus Padcev

Merck gets US FDA nod for Welireg, as trial with Moderna bears fruit

Merck reports mixed updates for cancer treatment, Keytruda

TOP NEWS: Merck hails Daiichi Sankyo partnership but will take charge

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

BLACK FRIDAY

Forexで最大60%オフ

1年間40％、2年間40％、*3年間60％

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Merck & Co Inc (0QAH) ニュース

Merck & Co Inc (0QAH)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

0QAH ニュース

IN BRIEF: Merck trial shows Koselugo effective in treating adults

Merck cuts earnings guidance as acquisitions weigh on bottom line

IN BRIEF: Merck and Daiichi Sankyo's patritumab effective in phase 3

TOP NEWS: Merck swings to second-quarter profit; trims profit guidance

Merck & Co enhances ophthalmology portfolio with EyeBio acquisition

Merck & Co raises annual outlook thanks to first quarter boost

IN BRIEF: Merck hails positive data on cervical cancer drug, Keytruda

Merck and Astellas drugs get priority review in US and Japan

TOP NEWS: Merck books 2023 growth despite gefapixant rejection hit

IN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon sale

Merck to buy Harpoon Therapeutics for about USD680 million

Astellas, Merck, Pfizer celebrate US approval for Keytruda plus Padcev

Merck gets US FDA nod for Welireg, as trial with Moderna bears fruit

Merck reports mixed updates for cancer treatment, Keytruda

TOP NEWS: Merck hails Daiichi Sankyo partnership but will take charge

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

BLACK FRIDAY

Forexで最大60%オフ

1年間40％、2年間40％、*3年間60％